[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654640":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":23,"studyPopulation":24,"armGroups":25,"interventions":19,"overallOfficials":19,"centralContacts":32,"locations":38,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":19,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":19,"enrollmentInfo":78,"targetDuration":19,"studyType":81,"phases":19,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University Hospitals Coventry and Warwickshire NHS Trust","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":19},[9,13],{"measure":10,"description":11,"timeFrame":12},"Blood results","Identifying and validating changes in miRNA expression","Baseline visit",{"measure":10,"description":11,"timeFrame":14},"12 week follow-up visit",[16,18],{"measure":10,"description":17,"timeFrame":12},"Identifying and validating changes in protein biomarker profiles",{"measure":10,"description":17,"timeFrame":14},null,{"allocation":19,"interventionModel":19,"interventionModelDescription":19,"primaryPurpose":19,"observationalModel":21,"timePerspective":22,"maskingInfo":19},"COHORT","PROSPECTIVE","To identify and validate changes in miRNA pre- and post- radical RT\u002Fchemo-RT (cohort 1) and pre- and post- IO-based complex SACT (cohort 2) and elucidate links between dysregulated miRNAs and clinical evaluations.\n\nTo identify and validate changes in protein biomarker profile (1,034 protein targets) pre- and post- radical RT\u002Fchemo-RT (cohort 1) and pre- and post- IO-based complex SACT (cohort 2) and to elucidate links between changes in proteins relevant to immune and inflammatory pathways and clinical evaluations.","Patients on treatment for cancer at UHCW NHS Trust",[26,29],{"label":27,"type":19,"description":28,"interventionNames":19},"Patients treated with RT","Patients treated with curative-intent RT\u002Fchemo-RT for lung or oesophageal cancer",{"label":30,"type":19,"description":31,"interventionNames":19},"Patients treated with SACT","Patients treated with IO-based complex SACT for any malignant solid tumour",[33],{"name":34,"role":35,"phone":36,"phoneExt":19,"email":37},"Hardip Sandhu, MBA, BSc, MSc, PhD","CONTACT","+442477 659305","ab1682@coventry.ac.uk",[39],{"facility":40,"status":41,"city":42,"state":19,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University Hospitals Coventry & Warwickshire NHS Trust","RECRUITING","Coventry","CV2 2DX","United Kingdom","UK",{"type":47,"coordinates":48},"Point",[49,50],-1.51217,52.40656,{"lat":50,"lon":49},[53,57,61],{"name":54,"role":35,"phone":55,"phoneExt":19,"email":56},"Raj Shrimali, MBBS, FRCR, FRCP, PhD","+44 2476 966197","Raj.Shrimali@uhcw.nhs.uk",{"name":58,"role":35,"phone":59,"phoneExt":19,"email":60},"Sean James","+442476 965248","sean.james@uhcw.nhs.uk",{"name":62,"role":63,"phone":19,"phoneExt":19,"email":19},"Raj Shrimali","PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[67],{"name":68,"class":6},"Coventry University","100654640","biomarkers-for-cancer-treatment-100654640",false,"NCT07803289","Biomarkers for Cancer Treatment","Characterising Circulating Biomarker Signatures From Diverse Cancer Treatment Modalities - A Pilot Study","Inclusion Criteria:\n\n* Adult patients (Age \\>18 years)\n* Histologically\u002FCytological confirmed solid tumour\n* Treated with radical RT or concurrent chemo-RT (Cohort 1) OR\n* Treated with chemo-IO or IO-IO combination (Cohort 2)\n* First-line treatment\n* Able to provide informed consent\n* Willing to comply with study procedures\n\nExclusion Criteria:\n\n* Contraindication for RT or chemotherapy (Cohort 1) OR\n* Contraindication for chemotherapy or IO (Cohort 2)\n* Use of chemotherapy or immunotherapy in the last 5 years. (Cohort 1) OR\n* Use of radical RT or chemo-RT within the thorax in the last 5 years. (Cohort 2)\n* Beyond first-line treatment (second line onwards)\n* Has more than 1 active cancer requiring treatment\n* Recent participation in an interventional study\n* Pregnant or breastfeeding women\n* On long term cytotoxics or immune-modulators for rheumatoid arthritis or connective tissue disorders or auto-immune disorders\n* Poor life expectancy, likely less than 6 months\n* Patients not likely to comply with treatment or the study","ALL","18 Years",{"count":79,"type":80},48,"ESTIMATED","OBSERVATIONAL","Circulating biomarkers, such as miRNAs and proteomics, undergo identifiable and measurable changes during and following treatment for cancer, compared to pre-treatment baseline. Some of these changes may be associated either with known treatment parameters or predictive for cardiac or lung toxicity.\n\nThe aim is to identify and validate changes following treatment for cancer, compared to pre-treatment baseline, as well as differential miRNA expression in two-group comparisons (patients receiving radical RT\u002FchemoRT for thoracic cancers versus IO-based complex SACT).",[84,85],"Cancer","Biomarker Discovery and Validation",[87,88,89,90,91],"miRNA","proteomics","blood biomarkers","cancer treatment","toxicity","2026-09-01",{"date":94,"type":95},"2026-09-03","ACTUAL",{"date":97,"type":95},"2026-05-01",{"date":99,"type":80},"2028-04-30",{"name":5,"class":6},1]